These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 33534236)
1. Tethered Liquid Perfluorocarbon Coating for 72 Hour Heparin-Free Extracorporeal Life Support. Roberts TR; Choi JH; Wendorff DS; Harea GT; Beely BM; Sieck KN; Douglass ME; Singha P; Dean JB; Handa H; Batchinsky AI ASAIO J; 2021 Jul; 67(7):798-808. PubMed ID: 33534236 [TBL] [Abstract][Full Text] [Related]
2. Heparin-Free Extracorporeal Life Support Using Tethered Liquid Perfluorocarbon: A Feasibility and Efficacy Study. Roberts TR; Harea GT; Singha P; Sieck KN; Beely BM; Wendorff DS; Choi JH; Ande S; Handa H; Batchinsky AI ASAIO J; 2020 Jul; 66(7):809-817. PubMed ID: 31453831 [TBL] [Abstract][Full Text] [Related]
3. Tethered-liquid omniphobic surface coating reduces surface thrombogenicity, delays clot formation and decreases clot strength ex vivo. Roberts TR; Leslie DC; Cap AP; Cancio LC; Batchinsky AI J Biomed Mater Res B Appl Biomater; 2020 Feb; 108(2):496-502. PubMed ID: 31069955 [TBL] [Abstract][Full Text] [Related]
4. Is anticoagulation with bivalirudin comparable to heparin for pediatric extracorporeal life support? Results from a high-volume center. Schill MR; Douds MT; Burns EL; Lahart MA; Said AS; Abarbanell AM Artif Organs; 2021 Jan; 45(1):15-21. PubMed ID: 32557733 [TBL] [Abstract][Full Text] [Related]
5. Do we need heparin coating for extracorporeal membrane oxygenation? New concepts and controversial positions about coating surfaces of extracorporeal circuits. Silvetti S; Koster A; Pappalardo F Artif Organs; 2015 Feb; 39(2):176-9. PubMed ID: 25041628 [TBL] [Abstract][Full Text] [Related]
6. Combination of polycarboxybetaine coating and factor XII inhibitor reduces clot formation while preserving normal tissue coagulation during extracorporeal life support. Naito N; Ukita R; Wilbs J; Wu K; Lin X; Carleton NM; Roberts K; Jiang S; Heinis C; Cook KE Biomaterials; 2021 May; 272():120778. PubMed ID: 33812214 [TBL] [Abstract][Full Text] [Related]
7. Challenges with Navigating the Precarious Hemostatic Balance during Extracorporeal Life Support: Implications for Coagulation and Transfusion Management. Andrews J; Winkler AM Transfus Med Rev; 2016 Oct; 30(4):223-9. PubMed ID: 27543261 [TBL] [Abstract][Full Text] [Related]
8. Femoral veno-arterial extracorporeal life support with minimal or no heparin. Aranki SF; Adams DH; Rizzo RJ; Couper GS; DeCamp MM; Fitzgerald DJ; Cohn LH Ann Thorac Surg; 1993 Jul; 56(1):149-55. PubMed ID: 8328846 [TBL] [Abstract][Full Text] [Related]
10. Venovenous Extracorporeal Membrane Oxygenation With Prophylactic Subcutaneous Anticoagulation Only: An Observational Study in More Than 60 Patients. Krueger K; Schmutz A; Zieger B; Kalbhenn J Artif Organs; 2017 Feb; 41(2):186-192. PubMed ID: 27256966 [TBL] [Abstract][Full Text] [Related]
11. Factor XII Silencing Using siRNA Prevents Thrombus Formation in a Rat Model of Extracorporeal Life Support. Umei N; Shin S; Lai A; Miller J; Roberts K; Strelkova D; Chaudhary N; Ichiba S; Sakamoto A; Whitehead K; Cook K ASAIO J; 2023 Jun; 69(6):527-532. PubMed ID: 36728837 [TBL] [Abstract][Full Text] [Related]
12. Activity of anticoagulant proteins on the polymer-coated and heparin-coated membranes in an extracorporeal circulation circuit. Tagaya M; Murataka T; Okano S; Handa H; Tanaka Y; Takahashi S Perfusion; 2023 Apr; 38(3):600-608. PubMed ID: 35098806 [TBL] [Abstract][Full Text] [Related]
13. Ex vivo testing of heparin-coated extracorporeal circuits: bovine experiments. Weerwind PW; van der Veen FH; Lindhout T; de Jong DS; Cahalan PT Int J Artif Organs; 1998 May; 21(5):291-8. PubMed ID: 9684912 [TBL] [Abstract][Full Text] [Related]
14. Pilot study evaluating a non-titrating, weight-based anticoagulation scheme for patients on veno-venous extracorporeal membrane oxygenation. Deatrick KB; Galvagno SM; Mazzeffi MA; Kaczoroswki DJ; Herr DL; Rector R; Hochberg E; Rabinowitz RP; Scalea TM; Menaker J Perfusion; 2020 Jan; 35(1):13-18. PubMed ID: 31122144 [TBL] [Abstract][Full Text] [Related]
15. A dual-action nitric oxide-releasing slippery surface for extracorporeal organ support: Dynamic in vitro hemocompatibility evaluation. Roberts TR; Harea GT; Zang Y; Devine RP; Maffe P; Handa H; Batchinsky AI J Biomed Mater Res B Appl Biomater; 2023 Apr; 111(4):923-932. PubMed ID: 36404401 [TBL] [Abstract][Full Text] [Related]
16. Anticoagulation with nafamostat mesilate during extracorporeal life support. Lang Y; Zheng Y; Qi B; Zheng W; Wei J; Zhao C; Gao W; Li T Int J Cardiol; 2022 Nov; 366():71-79. PubMed ID: 35850387 [TBL] [Abstract][Full Text] [Related]
17. Extracorporeal membrane oxygenation for postcardiotomy cardiogenic shock. Muehrcke DD; McCarthy PM; Stewart RW; Foster RC; Ogella DA; Borsh JA; Cosgrove DM Ann Thorac Surg; 1996 Feb; 61(2):684-91. PubMed ID: 8572788 [TBL] [Abstract][Full Text] [Related]
18. Modified surface coatings and their effect on drug adsorption within the extracorporeal life support circuit. Preston TJ; Ratliff TM; Gomez D; Olshove VE; Nicol KK; Sargel CL; Chicoine LG J Extra Corpor Technol; 2010 Sep; 42(3):199-202. PubMed ID: 21114222 [TBL] [Abstract][Full Text] [Related]
20. Prospective Side by Side Comparison of Outcomes and Complications With a Simple Versus Intensive Anticoagulation Monitoring Strategy in Pediatric Extracorporeal Life Support Patients. Yu JS; Barbaro RP; Granoski DA; Bauman ME; Massicotte MP; Lequier LL; Annich GM; Ryerson LM Pediatr Crit Care Med; 2017 Nov; 18(11):1055-1062. PubMed ID: 28922263 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]